aTyr Pharma (ATYR) Gains 5% After Securing FDA Protocol Approval for Phase 3 Sarcoidosis Study

aTyr Pharma (ATYR) stock surged 5% after securing FDA agreement on Phase 3 trial protocol for efzofitimod in pulmonary sarcoidosis, launching Q4 2026.

The post aTyr Pharma (ATYR) Gains 5% After Securing FDA Protocol Approval for Phase 3 Sarcoidosis Study appeared first on Blockonomi.